Hib Vaccine Safety

Institutional safety data for Haemophilus influenzae type b (Hib) vaccines. Clinical monitoring, manufacturer packages, and adverse event profiles.

Clinical Overview

Professional summary

Haemophilus influenzae type b (Hib) is a virulent bacterium responsible for severe invasive diseases, including bacterial meningitis, pneumonia, and acute epiglottitis. Prior to the introduction of the registry vaccines, Hib was the primary driver of bacterial meningitis in children under 5 years of age.

Contemporary immunization has resulted in a 99% reduction in disease incidence. These conjugate modules met all clinical safety and efficacy criteria established by the Food and Drug Administration (FDA).

Protects against Haemophilus influenzae type b, a primary driver of bacterial meningitis.

Highly effective in preventing pneumonia and epiglottitis in pediatric populations.

Clinical records indicate an exceptional safety profile since introduction.

Conjugate formulations provide durable, long-lasting immunological memory.

Available Registry Modules

Vaccine modules

Single-Antigen Modules

Ages: 2 months - 5 years

ActHIB (Sanofi)
Hiberix (GSK)

Combination Protocols

Multivalent series

Pentacel (Sanofi)
Vaxelis (MCM)

View titration analysis and administration schedules on official nodes.

Eligibility & Schedules

Protocol triage

Contraindications

Anaphylaxis to previous Hib series dose
Acute moderate-to-severe illness state
Pediatric age below 6 weeks

Adverse Reaction Profile

Expected and critical events

Local Reactions

Localized erythema (Redness)
Thermal induration (Warmth)
Injection site swelling

Systemic Reactions

Low-grade pyrexia (Fever)
Generalized lethargy
Minor irritability

Emergency Protocol

Verified safety: Hib vaccine remains one of the safest modules in the 2026 registry. Serious clinical events are statistically exceptional.

Safety Metadata Analysis

Monitoring summary

35+ Years

Surveillance Data

99%

Reduction in Incidence

Institutional Synthesis

Continuous active surveillance confirms that Hib vaccination benefits far outweigh statistically minimal risks, maintaining an exemplary safety profile across all pediatric cohorts.

Verified Source: CDC / WHO

Last global review: September 1, 2025. Content verified by HCP Connect clinical editorial staff in alignment with 2026 safety protocols.